Oseltamivir is the best available anti-influenza drug and has therefore been stockpiled worldwide in large quantities as part of influenza pandemic preparedness planning. The active metabolite oseltamivir carboxylate (OC) is stable and is not removed by conventional sewage treatment. Active OC has been detected in river water at concentrations up to 0.86 μg/L. Although the natural reservoir hosts of influenza A virus (IAV) are wild waterfowl that reside in aquatic environments, the ecologic risks associated with environmental OC release and its potential to generate resistant viral variants among wild birds has largely been unknown. However, in recent years a number of in vivo mallard (Anas platyrhynchos) studies have been conducted regarding the potential of avian IAVs to become resistant to OC in natural reservoir birds if these are drug exposed. Development of resistance to OC was observed both in Group 1 (N1) and Group 2 (N2, N9) neuraminidase subtypes, when infected ducks were exposed to OC at concentrations between 0.95 and 12 μg/L in their water. All resistant variants maintained replication and transmission between ducks during drug exposure. In an A(H1N1)/H274Y virus, the OC resistance mutation persisted without selective drug pressure, demonstrating the potential of an IAV with a permissive genetic background to acquire and maintain OC resistance, potentially allowing circulation of the resistant variant among wild birds. The experimental studies have improved the appreciation of the risks associated with the environmental release of OC related to resistance development of avian IAVs among wild birds. Combined with knowledge of efficient methods for improved sewage treatment, the observations warrant implementation of novel efficient wastewater treatment methods, rational use of antiviral drugs, and improved surveillance of IAV resistance in wild birds.

Keywords: influenza A; avian influenza; resistance; oseltamivir; environmental; mallard; antiviral resistance; sewage treatment

*Correspondence to: Anna Gillman, Section for Infectious Diseases, Department of Medical Sciences, Uppsala University, Ing 34, SE-75185 Uppsala, Sweden, Email: anna.gillman@medsci.uu.se

Received: 12 July 2016; Revised: 12 September 2016; Accepted: 13 September 2016; Published: 11 October 2016
circulating variants may not perfectly match the antigenicity of the chosen vaccine strains. Regarding pandemic vaccines, a major drawback is that they cannot be made in advance as the antigenicity remains unknown until the virus emerges and thus the final distribution of a new vaccine can only be achieved after several months (11, 12). Therefore, a cornerstone in the treatment and prevention of new human pathogenic influenza viruses, as well as of severe seasonal cases, is direct anti-influenza drugs.

**Neuraminidase inhibitors and resistance**

Since the widespread global resistance to the adamantane M2 ion channel inhibitors in the mid-2000s (13, 14), the neuraminidase inhibitors (NAIs) have been the best drugs available to treat severe influenza infections (15). Zanamivir (ZA) and oseltamivir have been globally approved since 1999, whereas peramivir and laninamivir have been approved in Japan and a few other countries since 2010 (13, 16).

Among the NAIs the orally available oseltamivir (Tamiflu®) is the most used and is the primary drug that has been stockpiled worldwide as part of pandemic preparedness planning (17, 18). After oral administration of the ethyl ester prodrug oseltamivir phosphate, which is converted by liver esterase, 75% of an oral dose reaches the plasma as active oseltamivir carboxylate (OC), which is then eliminated unchanged in the urine (19). OC and all other NAIs act by competitive binding to the extracellular enzymatic site of the neuraminidase (NA) protein. Thereby, the NA binding and the catalytic destruction of its sialic acid targets is inhibited and the release of newly formed virions from infected cells and viral spread through respiratory secretions is reduced (16). NA binding to the enzymatic target differs slightly between the structurally different neuraminidase (NA) proteins (20), which are phylogenetically grouped to Group 1 (including subtypes N1, N4, N5, N8) and Group 2 (including subtypes N2, N3, N6, N7 and N9) (1, 21).

The NA group–specific differences also have implications for which resistance-related amino acid substitutions may evolve under drug pressure (22, 23). Resistance to NAIs is primarily caused by amino acid substitutions in the NA protein leading to reduced binding of the drugs, either by substitution of active site residues or of framework residues (22, 24). In IAVs containing N1 NA proteins the most common resistance-related change seen in vivo is the framework substitution H274Y (N2 numbering, used hereafter), whereas in N2-containing viruses the framework E119V and active-site R292K substitutions are most commonly described (22, 25).

Resistance to OC and ZA was described in vitro during the drug development phases and was accompanied by the demonstration of reduced viral fitness of resistant variants (26–28). NAI treatment of IAV-infected humans may also generate resistant viruses and is primarily described following treatment with oseltamivir and occurs both in human (29–31) and avian viruses (22, 32, 33). Clinically, resistance to NAIs is associated with prolonged infections in children and in immunosuppressed patients (29, 34); and in A(H7N9) and HPAI A(H5N1) cases with high viral loads and severe clinical outcomes (32, 33). Following market introduction, the overall OC resistance in clinical settings was reported to be less than 1% in adults and 4% in children under 12 years of age but higher in hospitalized children, immunocompromised individuals, and in HPAI A(H5N1) infected patients (22). Although much less common than OC resistance (35), ZA resistance in ZA treated patients has also been described (22, 36).

However, raising more concern than selection for resistant variants by clinical treatment is the circulation of NAI-resistant human strains in the absence of selective drug pressure. This feature was primarily described in the seasonal A(H1N1) virus 2007–2009 when the circulating strain was OC resistant due to an H274Y substitution in NA, without selective drug exposure (37). In 2009, the resistant seasonal A(H1N1) virus was entirely replaced by the NAI-susceptible (though adamantane-resistant) pandemic A(H1N1)pdm09 virus. However, since 2010/2011, an increasing number of community cases with OC-resistant A(H1N1)pdm09 viruses have been reported without previous oseltamivir exposure; in nearly all instances the resistance has been conferred by the H274Y substitution in NA (38–41).

Avian IAVs of wild waterfowl have been tested for NAI susceptibility only to a very limited extent compared to human viruses, especially regarding subtypes other than those infecting humans (42). Two screening studies on avian N1 and N6 subtypes, each containing fewer than 100 samples mainly collected from North America between 1976 and 2010, as well as a European study with 21 samples collected between 2002 and 2005, did not detect naturally occurring high-level resistance among wild bird avian IAVs (42–44).

**Environmental pollution with NAIs**

After administration of both oseltamivir and ZA, 75–80% of the active OC and ZA are excreted by urine or feces (19, 45). Both components are poorly removed by conventional sewage treatment and therefore end up in aquatic environments (46, 47). OC is the most studied substance, both regarding drug measurements in aquatic environments and regarding experimental studies on degradation and removal of the metabolite from water.

There is a correlation between the amount of oseltamivir that is prescribed to patients and the OC concentrations detected in effluents of sewage treatment plants (STPs) and in river water, with higher drug concentrations in STP effluents (48–53). It is however the presence of
active drugs in aquatic environments that can be expected to have an ecological effect.

In Japan, which accounts for over 70% of the global oseltamivir prescription (54, 55), numerous environmental measurements over the last 5–10 years have detected OC in river water in the range of a few 100 ng/L up to 865 ng/L (48, 51, 56–60). Studies in a number of European countries have detected OC in river water at average concentrations of approximately 50 ng/L, with a range up to 200 ng/L (49, 50, 52, 61, 62). Samples from the Rhine River at the border between Germany, France, and Switzerland, contained high concentrations of non-metabolized OP relative to OC (OP/OC ratio 13.1 as compared to <1 in STP effluents), indicating release from drug manufacturing (in Switzerland) in addition to sewage discharge (52).

The lower use of ZA, peramivir, and laninamivir as compared to OC is reflected in lower levels of active drugs released to aquatic environments. In Japan, drug concentrations of up to 59 ng/L of ZA, 11 ng/L of peramivir, and 9 ng/L of laninamivir have been measured in river water, with dynamics that are correlated with the number of influenza cases during the influenza season (53, 58, 60).

Environmental risk assessment of NAIs in aquatic systems includes evaluation of eco-toxicological effects and of direct antiviral effects on naturally circulating IAVs, including the potential for resistance development. There is a lack of knowledge regarding the eco-toxicological effects by OC, and prediction studies by mathematical modeling have led to varying conclusions regarding toxic effects on algae and fish (63–66).

**Removal of oseltamivir by sewage water treatment**

Conventional STPs use different techniques to remove waste products, usually a combination of mechanical treatment followed by chemical and biological (active sludge) treatment (46, 52, 59). Measurements of pharmaceuticals from influents and effluents of conventional STPs have demonstrated between 0% (49, 59) and 59% OC removal by the treatment (52). Experimental studies have demonstrated that OC is not removed by conventional sewage treatment (46) nor degraded by UV light exposure (46, 67), which often is an important degradation mechanism of drug metabolites in the environment (68).

In studies investigating other potential degradation methods, bacterial strains able to degrade and use OC as their sole carbon and energy source (a *Nocardioides* sp. and a *Flavobacterium* sp.) were isolated from environmental water sediments, suggesting biological degradation pathways of OC (69). Accordingly, in several degradation studies in water, microbial processes were demonstrated to be important for the dissipation of OC from waste water. OC removal can be increased by addition of active microbial sludge (70, 71), active sediments from natural waters (69, 72), and by fungal (*Phanerochaete chrysosporium*) exposure (73). The results of biodegradation studies have led to suggestions for bioremediation approaches in sewage treatment (69, 72), though their efficiency might be questioned if the OC load were very high, that is in a pandemic situation (71).

Adding ozone treatment to the conventional methods of wastewater treatment has proven very efficient in removing OC and other NAIs experimentally (53, 74). Confirming the experimental data, drug measurements from STP influents and effluents at units that use ozone treatment in addition to conventional techniques have repeatedly demonstrated significantly lower concentrations of released drugs as compared to conventional STPs. Over 85% of all NAIs are removed by adding a tertiary sewage treatment with ozone (51, 53, 59, 60, 75).

**Influenza A in the natural hosts**

The natural reservoir host of IAV is wild waterfowl, primarily Charadriiformes (in particular gulls, terns, and waders) and Anseriformes (in particular ducks, geese, and swans) (2, 3). Most subtype combinations of the 16 hemagglutinin (HA) and 9 NA surface proteins can be detected in wild waterfowl. Despite more pronounced subtype diversity among shorebird viruses, viral prevalence is highest in dabbling ducks (76, 77), among which the mallard (*Anas platyrhynchos*) is considered to be the most common IAV host species (78). During the autumn migration of birds in the Northern Hemisphere, the IAV prevalence typically peaks in dabbling ducks at up to 60% compared to 0.4–2% at wintering grounds (2, 3, 79). On the contrary, in the Delaware Bay on the North American east coast IAV prevalence is exceptionally high in shorebirds during the spring migration with over 10% prevalence, which is much higher than elsewhere and coincides with the congregation of waders and gulls foraging for horseshoe crab eggs (3, 76, 77, 80, 81).

In wild waterfowl IAVs cause an intestinal tract infection, and although large amounts of virus are shed in feces the infection is relatively asymptomatic (2, 82, 83). The temporal and spatial dynamics, as well as the evolution of IAVs in the natural hosts, are closely related to the ecology, immunology, and migration of the birds (3). As dabbling ducks switch breeding grounds between years, there are opportunities for viral transmission to different subpopulations over wide geographical areas (3, 78, 84). Perpetuation of low pathogenic avian influenza (LPAI) viruses in wild waterfowl year round is suggested to be a combination of 1) continuous transmission to juvenile and non-immune ducks at breeding and pre-migration congregation areas; 2) spread of virus with migrating birds; and 3) low prevalence circulation in resident ducks during the winter season in temperate locations (2, 85, 86). In addition, IAVs are known to stay infectious for a long time in lake water (2); freezing of viruses in lakes at breeding areas with...
reinfection of birds the following season is suggested to be another mechanism for viral perpetuation (78).

The genetic variability of wild waterfowl viruses is much greater than that of IAVs in other hosts, including combinations of most HAs and NAs without persisting sublineages (2) and a high diversity between HA and NA subtypes as well as of the nonstructural (NS) gene (87, 88). There is a continuous emergence of new viral variants, achieved both by frequent point mutations (genetic drift) (89, 90) and, typical for the segmented IAV genome, by reassortment events (genetic shift), which occur at a high frequency as a result of very common coinfections with more than one IAV in wild waterfowl (86, 87, 91).

**Risk for resistant IAV of wild waterfowl**

Despite the fact that natural IAV hosts reside in aquatic environments potentially polluted by NAIs, resistance screening of avian IAVs carried by wild waterfowl has to date been limited, as discussed above. Experimental *in vivo* systems testing the hypothesis that OC exposure of IAV-infected natural host birds leads to resistance development have confirmed that avian IAVs containing both Group 1 and Group 2 NAs become resistant when infected mallards are exposed to OC in their water (92–95). When mallards experimentally infected with an avian A(H1N1) virus were exposed to 0.95 μg/L of OC in their water, OC resistance conferred by the H274Y substitution in NA evolved. Despite the H274Y resistance substitution, leading to highly reduced OC susceptibility, infectivity and transmissibility between mallards was maintained (92). In a subsequent study in the same experimental model with the resistant A(H1N1)/H274Y variant in which drug exposure was removed from infected mallards, the resistant variant persisted without drug pressure (96). Maintenance of a resistant genotype and phenotype without selective drug pressure suggests a maintained viral fitness as compared to wild-type virus. In the same *in vivo* mallard model an A(H6N2) virus acquired high-level OC resistance conferred by the R292K substitution when ducks were exposed to 12 μg/L of OC (94), while a low pathogenic A(H7N9) virus acquired the resistance-related I227T framework substitution at 2.5 μg/L of OC exposure (95). Infectivity and transmissibility between mallards was maintained during drug pressure by both of the viruses, but when the resistant A(H6N2)/R292K variant was allowed to replicate in mallards without drug pressure it reverted to wild type, confirming a reduced viral fitness of the resistant variant (97). In another *in vivo* mallard model, selection for the framework NA substitution E119V in a low pathogenic A(H5N2) virus was demonstrated when infected ducks were exposed to 1 μg/L of OC in water. The resistant A(H5N2)/E119V variant dominated the viral population and was transmissible between mallards, but it was outcompeted by wild-type virus when drug exposure was removed (93).

The available results from experimental OC exposure studies of avian IAVs demonstrate that both Group 1 and Group 2 viruses may acquire resistance if the natural host birds are exposed to low levels of OC in their water. The propensity to maintain the acquired resistance without drug pressure varies between NA groups, subtypes, and strains. The different propensity is influenced by the subtype-specific resistance substitutions, as a framework substitution like H274Y may be compensated for more easily without compromising viral fitness than an active site residue, like R292K. Clearly, the exact genetic context in which a resistance mutation is induced is paramount for the potential of its persistence without drug pressure and for the potential of the resistant viral variant to circulate among wild birds.

In human IAVs, resistance to OC occurs in clinical settings both in A(H3N2) and in A(H1N1) viruses (22), but thus far only resistant A(H1N1) strains have circulated in the community without drug pressure. The dependence on the genetic context in which a resistance mutation is acquired is demonstrated by the permissive mutations compensating for reduced viral fitness. Different permissive mutations have been identified for OC-resistant human A(H1N1) viruses in which the resistance is conferred by the H274Y substitution, including the seasonal virus in 2007–2009 (37, 98, 99) and OC-resistant A(H1N1)/2009pdm/H274Y community clusters in Australia and Japan (40, 41, 100).

In the experimental OC-exposure mallard studies, the drug concentrations at which resistant variants emerged varied between studies. In the environment, numerous measurements of OC in the main river systems in Japan have confirmed concentrations up to 0.86 μg/L (57), while European studies at several river sites have detected OC in the range of 0.02–0.2 μg/L (50, 52, 62). The drug concentrations at which avian IAVs experimentally developed resistance in mallards were thus above the environmental ones detected to date. However, they are in the same magnitude, and as the OC levels in river water vary with oseltamivir consumption (48, 61) and with the quality of sewage treatment (51) higher environmental concentrations may occasionally occur. Although the exposure of aquatic birds may be lower at STP effluents, it should be noted that OC concentrations in these locations are multiples higher than in river water (48, 49, 51).

As IAVs acquire resistance mutations at various drug concentrations, predictions on the amount of pharmaceuticals in the environment that constitute a risk for resistance induction are uncertain. The high genetic variability of avian IAVs (87) provides the opportunity for genetic contexts to be permissive if selective pressure for resistance occurs. The experimental results from OC exposure studies over the last couple of years (92–97) have contributed to the estimations of the ecological risks related to the release of active NAIs to the environment.
The results indicate that there is a risk for the evolution of resistant avian IAVs in the natural host birds.

Knowledge on the levels of OC released to aquatic environments (50, 57), combined with the observations of IAV resistance development in experimentally exposed host birds, warrants broad implementation of new efficient sewage water treatment techniques (59) and rational use of available NAIs.

It remains an area of research whether an OC-resistant waterfowl-adapted IAV may maintain a resistance trait through the complex evolutionary process to a new emerging human pathogenic virus. If such a virus were to emerge and be highly pathogenic to humans, the current stockpiles of oseltamivir would be of no use and the public health impact of a pandemic would be substantially worsened. Other future areas of research include increased OC resistance screening of avian IAVs of wild waterfowl, both regarding the number of tested samples and geographic regions, as well as the evaluation of the potential for resistance development to other NAIs in natural host birds. A number of new anti-influenza drugs are expected to be introduced to the market within the coming years (13). The development of new influenza drugs needs to include studies on their ecologic and environmental impact, including their potential to generate resistant IAVs in wild birds.

Conflict of interest and funding

The author has received financial support from the Swedish Research Council FORMAS and from the Family Olinder-Nielsen’s Foundation.

References

1. Fields BN, Knipe DM, Howley PM. Fields’ virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
2. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992; 56: 152–79.
3. Olsen B, Munster VJ, Wallensten A, Waldenström J, Osterhaus AD, Fouchier RA. Global patterns of influenza A virus in wild birds. Science 2006; 312: 384–8.
4. Brockwell-Staats C, Webster RG, Webby RJ. Diversity of influenza viruses in swine and the emergence of a novel human pandemic influenza A (H1N1). Influenza Other Respir Viruses 2009; 3: 207–13.
5. Cox NJ, Subbarao K. Global epidemiology of influenza: past and present. Annu Rev Med 2000; 51: 407–21.
6. Monto AS, Webster RG. Influenza pandemics: history and lessons learned. In: Webster RG, Monto AS, Braciale TJ, Lamb RA, eds. Textbook of influenza. 2nd ed. Oxford, UK: Wiley; 2013, pp. 20–34.
7. To KK, Chan JF, Chen H, Li L, Yuen KY. The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities. Lancet Infect Dis 2013; 13: 809–21.
8. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358: 261–73.
9. Tanner WD, Toth DJ, Gundlapalli AV. The pandemic potential of avian influenza A(H7N9) virus: a review. Epidemiol Infect 2015; 143: 3359–74.
10. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59: 1–62.
11. Partridge J, Kiery MP. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009–2010 and comparison with previous estimates and global action plan targets. Vaccine 2010; 28: 4709–12.
12. Nguyen-Van-Tam JS, Bree J. Pandemic preparedness and response. In: Webster RG, Monto AS, Braciale TJ, Lamb RA, eds. Textbook of influenza. 2nd ed. Oxford, UK: Wiley; 2013, pp. 453–69.
13. Webster RG, Govorkova EA. Continuing challenges in influenza. Ann N Y Acad Sci 2014; 1323: 115–39.
14. WHO. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012. Wkly Epidemiol Rec 2012; 87: 369–74.
15. Hurt AC, Besselaar TG, Daniels RS, Ermel J, Fry A, Gubareva L, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015. Antiviral Res 2016; 132: 178–85.
16. Ison MG, Hay A. Antivirals: targets and use. In: Webster RG, Monto AS, Braciale TJ, Lamb RA, eds. Textbook of influenza. 2nd ed. Oxford, UK: Wiley; 2013, pp. 392–418.
17. Patel A, Gorman SE. Stockpiling antiviral drugs for the next influenza pandemic. Clin Pharmacol Ther 2009; 86: 241–3.
18. Wan Po AL, Farndon P, Palmer N. Maximizing the value of drug stockpiles for pandemic influenza. Emerg Infect Dis 2009; 15: 1866–7.
19. Smith JR, Rayner CR, Donner B, Wollenhaupt M, Klumpp K, Dukowski R. Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience. Adv Ther 2011; 28: 927–59.
20. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006; 443: 45–9.
21. Russel RJ, Gamblin SJ, Skehel JJ. Influenza glycoproteins: hemagglutinin and neuraminidase. In: Webster RG, Monto AS, Braciale TJ, Lamb RA, eds. Textbook of influenza. 2nd ed. Oxford, UK: Wiley; 2013, pp. 67–100.
22. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 2013; 98: 174–85.
23. McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses 2013; 7(Suppl 1): 25–36.
24. Colman PM, Hoyme PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 1993; 67: 2972–80.
25. Ferraris O, Lina B. Mutations of neuraminidase implicated in resistance to neuraminidase inhibitors. Influenza Other Respir Viruses 2010 and com-
26. Russell RJ, Gamblin SJ, Skehel JJ. Influenza glycoproteins: hemagglutinin and neuraminidase. In: Webster RG, Monto AS, Braciale TJ, Lamb RA, eds. Textbook of influenza. 2nd ed. Oxford, UK: Wiley; 2013, pp. 67–100.
27. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 2013; 98: 174–85.
28. McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses 2013; 7(Suppl 1): 25–36.
29. Colman PM, Hoyme PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 1993; 67: 2972–80.
30. Ferraris O, Lina B. Mutations of neuraminidase implicated in resistance to neuraminidase inhibitors. J Clin Virol 2008; 41: 13–19.
31. Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, Wu H, et al. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998; 42: 3234–41.
32. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidinono- Neu5Ac2en. J Virol 1997; 71: 3385–90.

Citation: Infection Ecology and Epidemiology 2016, 6: 32870 - http://dx.doi.org/10.3402/iee.v6.32870

(page number not for citation purpose)
28. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, Hart GI, et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998; 72: 2456–62.

29. Kiso M, Mitamura K, Sakai-Tagawa Y, Shinraishi K, Kawakami C, kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364: 759–65.

30. Whitley RJ, Boucher CA, Lina B, Nguyen-Van-Tam JS, Osterhaus A, Schutten M, et al. Global assessment of resistance to neuraminidase inhibitors, 2008–2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis 2013; 56: 1197–205.

31. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001; 183: 523–31.

32. De Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, et al. Association of multiple influenza A (H7N9) virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381: 2273–9.

33. Eshaghi A, Shalhoub S, Rosenfeld P, Li A, Higgins RR, Thorlund K, Awad T, Boivin G, Thabane L. Systematic review and meta-analysis of oseltamivir for treatment of uncomplicated seasonal influenza in otherwise healthy adults and children. Cochrane Database Syst Rev 2012; 10: CD007932.

34. Moscona A. Global transmission of oseltamivir-resistant influenza A (H1N1) virus. N Engl J Med 2009; 360: 953–6.

35. Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, Pan CY, et al. Mutations in conserved X320 residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998; 72: 2456–62.

36. Moscona A. Global transmission of oseltamivir-resistant influenza A (H1N1) virus. N Engl J Med 2009; 360: 953–6.

37. Moscona A. Global transmission of oseltamivir-resistant influenza A (H1N1) virus. N Engl J Med 2009; 360: 953–6.

38. Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, Pan CY, et al. Mutations in conserved X320 residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998; 72: 2456–62.

39. Lackenby A, Moran Gilad J, Pebody R, Miah S, Calayoyd L, Bolotin S, et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A (H1N1)pdm09 virus, United Kingdom, winter 2010/11. Euro Surveill 2011; 16: 1–16.

40. Takashita E, Kiso M, Fujisaki S, Yokoyama M, Nakamura K, Shirakura M, et al. Characterization of a large cluster of influenza A (H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013–2014 influenza season in Japan. Antivirals 2015; 59: 2607–17.

41. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Gehrig N, et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 2011; 365: 2541–2.

42. Stoner TD, Krauss S, Turner JC, Seiler P, Negovetich NJ, Stallknecht DE, et al. Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir. Antiviral Res 2012; 93: 322–9.

43. Orozovic G, Orozovic K, Järlhult JD, Olsen B. Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in Sweden. PLoS One 2014; 9: e89306.

44. Stoner TD, Krauss S, DuBois RM, Negovetich NJ, Stallknecht DE, Senne DA, et al. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype. J Virol 2010; 84: 9800–9.

45. LIFproduktresumé. Produktresumé FASS Relenza. Läkemedelsverket. [cited 19 January 2015].

46. Fick J, Lindberg RH, Tysklin M, Haemig PD, Waldenström J, Wallensten A, et al. Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. PLoS One 2007; 2: e986.

47. Jain S, Kumar P, Vyas RK, Pandit P, Dalai AK. Occurrence and removal of antiviral drugs in environment: a review. Water Air Soil Pollut 2013; 224: 1–19.

48. Azuma T, Nakada N, Yamashita N, Tanaka H. Synchronous dynamics of observed and predicted values of anti-influenza drugs in environmental waters during a seasonal influenza outbreak. Environ Sci Technol 2012; 46: 12873–81.

49. Leknes H, Sturtzel IE, Dye C. Environmental release of oseltamivir from a Norwegian sewage treatment plant during the 2009 influenza A (H1N1) pandemic. Sci Total Environ 2012; 414: 632–8.

50. Singer AC, Järlhult JD, Grabic R, Khan GA, Lindberg RH, Fedorova G, et al. Intra- and inter-pandemic variations of antiviral, antibiotics and decongestants in wastewater treatment plants and receiving rivers. PLoS One 2014; 9: e108621.

51. Ghosh GC, Nakada N, Yamashita N, Tanaka H. Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiifu), detected in sewage discharge and river water in Japan. Environ Health Perspect 2010; 118: 103–7.

52. Prasse C, Schlusener M, Schulz R, Ternes TA. Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relevance? Environ Sci Technol 2010; 44: 1728–35.

53. Azuma T, Ishiuchi H, Inoyama T, Teranishi Y, Yamaoka M, Sato T, et al. Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan. PLoS One 2015; 10: e0131412.

54. Tashiro M, McKimm-Breschkin JL, Saito T, Klimov A, Macken C, Zambon M, et al. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996–2007. Antivir Ther 2010; 14: 751–61.

55. Hoffman-La-RocheInc. Pediatric Advisory Committee Briefing Document for Tamiflu® (RO 64-0796) PAC Briefing Document. Nutley, New Jersey: Hoffmann-La Roche Inc; 2007.

56. Söderström H, Järlhult JD, Olsen B, Lindberg RH, Tanaka H, Fick J. Detection of the antiviral drug oseltamivir in aquatic environments. PLoS One 2009; 4: e6064.

57. Takanami R, Ozaki H, Giri RR, Taniguchi S, Hayashi S. Detection of oseltamivir-carboxylate in Neya River, Osaka Japan. J Water Environ Technol 2010; 8: 363–70.

58. Takanami R, Ozaki H, Giri RR, Taniguchi S, Hayashi S. Detection of oseltamivir-carboxylate in Neya River, Osaka Japan. Environ Health Perspect 2010; 118: 103–7.

59. Takanami R, Ozaki H, Giri RR, Taniguchi S, Hayashi S. Detection of oseltamivir-carboxylate in Neya River, Osaka Japan. Environ Health Perspect 2010; 118: 103–7.

60. Takanami R, Ozaki H, Giri RR, Taniguchi S, Hayashi S. Detection of oseltamivir-carboxylate in Neya River, Osaka Japan. Environ Health Perspect 2010; 118: 103–7.

61. Erfkamp H, Loos M, Weisbrod RT, Parkin NJ, Agawin S, et al. Oseltamivir and peramivir: evaluation of their efficacy and safety in a phase IIa clinical trial in patients infected with influenza A (H1N1)pdm09. Open Antiviral Ther 2010; 3: 205–16.
61. Singer AC, Järhult JD, Grabic R, Khan GA, Fedorova G, Fick J, et al. Compliance to oseltamivir among two populations in Oxfordshire, United Kingdom affected by influenza A(H1N1)pdm09, November 2009 – a waste water epidemiology study. PLoS One 2013; 8: e60221.

62. Goncalves C, Perez S, Osorio V, Petrovic M, Alpendurada MF, Barcelo D. Photofate of oseltamivir (Tamiflu) and oseltamivir carboxylate under natural and simulated solar irradiation: kinetics, identification of the transformation products, and environmental occurrence. Environ Sci Technol 2011; 45: 4307–14.

63. Chen WY, Lin CJ, Liao CM. Assessing exposure risks for aquatic organisms posed by Tamiflu use under seasonal influenza and pandemic conditions. Environ Pollut 2014; 184: 377–84.

64. Straub JO. An environmental risk assessment for oseltamivir (Tamiflu) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions. Ecotoxicol Environ Saf 2009; 72: 1625–34.

65. Singer AC, Johnson AC, Anderson PD, Snyder SA. Reassessing the risks of Tamiflu use during a pandemic to the Lower Colorado River. Environ Health Perspect 2008; 116: A285–6.

66. Singer AC, Nunn MA, Gould EA, Johnson AC. Potential risks associated with the proposed widespread use of Tamiflu. Environ Health Perspect 2007; 115: 102–6.

67. Bartels P, von Tumpling W Jr. The environmental fate of the antiviral drug oseltamivir carboxylate in different waters. Sci Total Environ 2008; 405: 215–25.

68. Boreen AL, Arnold WA, McNell K. Photodegradation of pharmaceuticals in the aquatic environment: a review. Aquat Sci 2003; 65: 320–41.

69. Accinelli C, Sacca ML, Fick J, Mencarelli M, Lindberg R, Olsen B. Dissipation and removal of oseltamivir (Tamiflu) in different aquatic environments. Chemosphere 2010; 79: 891–7.

70. Accinelli C, Caracciolo AB, Grenni P. Degradation of the antiviral drug oseltamivir carboxylate in surface water samples. Int J Environ Anal Chem 2007; 87: 579–87.

71. Slater FR, Singer AC, Turner S, Barr JJ, Bond PL. Pandemic pharmaceutical dosing effects on wastewater treatment: no adaptation of activated sludge bacteria to degrade the antiviral drug oseltamivir (Tamiflu(R)) and loss of nutrient removal performance. FEMS Microbiol Lett 2011; 315: 17–22.

72. Sacca ML, Accinelli C, Fick J, Lindberg R, Olsen B. Environmental fate of the antiviral drug Tamiflu in two aquatic ecosystems. Chemosphere 2009; 75: 28–33.

73. Accinelli C, Sacca ML, Batissom I, Fick J, Mencarelli M, Grabic R. Removal of oseltamivir (Tamiflu) and other selected pharmaceuticals from wastewater using a granular bioplastic formulation entrapping propagules of Phanerochaete chrysosporium. Chemosphere 2010; 81: 436–43.

74. Mestankova H, Schirmer K, Escher BI, von Gunten U, Canonica S. Removal of the antiviral agent oseltamivir and its biological activity by oxidative processes. Environ Pollut 2012; 161: 30–5.

75. Fedorova G, Grabic R, Nyhlen J, Järhult JD, Söderström H. Fate of three anti-influenza drugs during ozonation of wastewater effluents – degradation and formation of transformation products. Chemosphere 2016; 150: 723–30.

76. Munster VJ, Baas C, Lexmond P, Waldenström J, Wallensten A, Fransson T, et al. Spatial, temporal, and species variation in prevalence of influenza A viruses in wild migratory birds. PLoS Pathog 2007; 3: e61.

77. Krauss S, Walker D, Pryor SP, Niles L, Chenglong L, Hinshaw VS, et al. 2004. Influenza A viruses of migrating wild aquatic birds in North America. Vector Borne Zoonotic Dis 2004; 4: 177–89.

78. Fouchier RAM, Guan Y. Ecology and evolution of influenza viruses in wild and domesticated birds. In: Webster RG, Monto AS, Braciale TJ, Lamb RA, eds. Textbook of influenza. Oxford, UK: Wiley; 2013, pp. 175–89.
infected mallards are exposed to low levels of oseltamivir in water. Antimicrob Agents Chemother 2015; 59: 5196–202.
96. Gillman A, Muradrasoli S, Söderström H, Holmberg F, Latorre-Margalef N, Tolf C, et al. Oseltamivir-resistant influenza A (H1N1) virus strain with an H274Y mutation in neuraminidase persists without drug pressure in infected mallards. Appl Environ Microbiol 2015; 81: 2378–83.
97. Gillman A, Muradrasoli S, Mardnas A, Söderström H, Fedorova G, Lowenthal M, et al. Oseltamivir resistance in influenza A(H6N2) caused by an R292K substitution in neuraminidase is not maintained in mallards without drug pressure. PLoS One 2015; 10: e0139415.
98. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010; 328: 1272–5.
99. Duan S, Govorkova EA, Bahl J, Zaraket H, Baranovich T, Seiler P, et al. Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses. Nat Commun 2014; 5: 5029.
100. Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, et al. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog 2014; 10: e1004065.